Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS Takes Second Shot At Mandating “Trial Size” Prescriptions For Part D; Estimates Savings At $2.5 Billion By 2018

Executive Summary

CMS once again has proposed mandating that Medicare Part D prescription drug plan sponsors offer a “trial size” of first-fill prescriptions for medications treating chronic conditions and, in a step further than the previous effort, mandated that the cost-sharing be prorated based on the daily cost of the drug.

You may also be interested in...



CMS Adopts Trial-Size Prescriptions For Part D, Delays Implementation

CMS mandates that Part D plans offer prescriptions filled for less than a 30-day period at a daily cost-sharing rate, with a few stated exceptions, but delays implementation until the 2014 plan year.

PhRMA Urges Caution In Implementing Part D “Trial-Size” Prescriptions

The Pharmaceutical Research and Manufacturers of America, as well as pharmacy and PBM groups, recommend that CMS test its proposed policy to institute trial-size prescriptions before implementing it on a widespread basis to Medicare Part D.

CMS Targeting LTC Facility Overprescribing, Citing Antipsychotics

The Centers for Medicare and Medicaid Services is proposing a new Medicare requirement that consulting pharmacists serving long-term care facilities maintain independence from the facility to help avoid drug “overprescribing and overutilization.”

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS053847

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel